Glucose metabolic profiles evaluated by PET associated with molecular characteristic landscape of gastric cancer

Bae, Seong-Woo; Berlth, Felix; Jeong, Kyoungyun; Park, Ji‐Hyeon; Choi, Jong Ho; Park, Shin-Hoo; Suh, Yun Suhk; Kong, Seong Ho; Park, Do Joong; Lee, Hyuk Joon; Lee, Charles; Kim, Jong‐Il; Youn, Hyewon; Choi, Hongyoon; Cheon, Gi Jeong; Kang, Keon Wook; Yang, Han Kwang

doi:10.1007/s10120-021-01223-3

Cited by 4 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hemoglobin subunit theta 1 (HBQ1) is often used as an indicator related to tumor metabolism. When patients with breast cancer were treated with the combination of bevacizumab and doxorubicin, HBQ1 was often differentially expressed (Borgan et al, 2013;Bae et al, 2022) and IGKV1D-8 was primarily involved in immune response (Gaudet et al, 2011). However, there have been a few reports on AC023449.…”

Section: Discussionmentioning

confidence: 99%

New Progress in Cancer Biomarkers and Therapy

2024

Frontiers Research Topics

View full text Add to dashboard Cite

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers journal seriesThe Frontiers journal series is a multi-tier and interdisciplinary set of openaccess, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers journal series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to qualityEach Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public -and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics?Frontiers Research Topics are very popular trademarks of the Frontiers journals series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

show abstract

Section: Discussionmentioning

confidence: 99%

New Progress in Cancer Biomarkers and Therapy

2024

Frontiers Research Topics

View full text Add to dashboard Cite

show abstract

“…Hemoglobin subunit theta 1 (HBQ1) is often used as an indicator related to tumor metabolism. When patients with breast cancer were treated with the combination of bevacizumab and doxorubicin, HBQ1 was often differentially expressed ( Borgan et al, 2013 ; Bae et al, 2022 ) and IGKV1D-8 was primarily involved in immune response ( Gaudet et al, 2011 ). However, there have been a few reports on AC023449.2 and IGKV1D-8 ( Alberici et al, 2018 ; Treffers et al, 2018 ; Dai et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Effective TME-related signature to predict prognosis of patients with head and neck squamous cell carcinoma

Wan,

Li,

Pan

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Introduction: The tumor microenvironment (TME) is crucial for the development of head and neck squamous cell carcinoma (HNSCC). However, the correlation of the characteristics of the TME and the prognosis of patients with HNSCC remains less known.Methods: In this study, we calculated the immune and stromal cell scores using the “estimate” R package. Kaplan-Meier survival and CIBERSORT algorithm analyses were applied in this study.Results: We identified seven new markers: FCGR3B, IGHV3-64, AC023449.2, IGKV1D-8, FCGR2A, WDFY4, and HBQ1. Subsequently, a risk model was constructed and all HNSCC samples were grouped into low- and high-risk groups. The results of both the Kaplan-Meier survival and receiver operating characteristic curve (ROC) analyses showed that the prognosis indicated by the model was accurate (0.758, 0.756, and 0.666 for 1-, 3- and 5-year survival rates). In addition, we applied the CIBERSORT algorithm to reveal the significant differences in the infiltration levels of immune cells between the two risk groups.Discussion: Our study elucidated the roles of the TME and identified new prognostic biomarkers for patients with HNSCC.

show abstract

“…There has also been the suggestion that the differentiated phenotype can alternatively be divided into gastric and intestinal subtypes, related to the cell of origin and the presence of mucin (gastric subtype) [ 17 ]. The metabolic profile of gastric carcinoma is highly variable by FDG PET-CT, and may reflect molecular and histologic growth-type differences in gastric carcinoma [ 18 ]. Whether FDG PET-CT is useful in staging non-GE junction gastric cancer is controversial.…”

Section: Gastric Carcinomamentioning

confidence: 99%

PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies

Koppula

Fine

Salem

et al. 2022

Cancers

View full text Add to dashboard Cite

PET-CT is an advanced imaging modality with many oncologic applications, including staging, assessment of response to therapy, restaging and longitudinal surveillance for recurrence. The goal of this series of six review articles is to provide practical information to providers and imaging professionals regarding the best use of PET-CT for specific oncologic indications, and the potential pitfalls and nuances that characterize these applications. In the third of these review articles, key tumor-specific clinical information and representative PET-CT images are provided to outline the role that PET-CT plays in the management of patients with gastrointestinal malignancies. The focus is on the use of 18F fluorodeoxyglucose (FDG), rather than on research radiopharmaceuticals under development. Many different types of gastrointestinal tumors exist, both pediatric and adult. A discussion of the role of FDG PET-CT for all of these is beyond the scope of this review. Rather, this article focuses on the most common adult gastrointestinal malignancies that may be encountered in clinical practice. The information provided here will provide information outlining the appropriate role of PET-CT in the clinical management of patients with gastrointestinal malignancies for healthcare professionals caring for adult cancer patients. It also addresses the nuances and provides interpretive guidance related to PET-CT for imaging providers, including radiologists, nuclear medicine physicians and their trainees.

show abstract

Glucose metabolic profiles evaluated by PET associated with molecular characteristic landscape of gastric cancer

Cited by 4 publications

References 33 publications

New Progress in Cancer Biomarkers and Therapy

New Progress in Cancer Biomarkers and Therapy

Effective TME-related signature to predict prognosis of patients with head and neck squamous cell carcinoma

PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies

Contact Info

Product

Resources

About